o-Carbonyl arylboronic acids such as 2-formylphenylboronic
acid (2-FPBA) are employed in biocompatible conjugation reactions
with the resulting iminoboronate adduct stabilized by an intramolecular
N–B interaction. However, few studies have utilized these reagents
as active site-directed enzyme inhibitors. We show that 2-FPBA is
a potent reversible, slow-onset inhibitor of mandelate racemase (MR),
an enzyme that has served as a valuable paradigm for understanding
enzyme-catalyzed abstraction of an α-proton from a carbon acid
substrate with a high pK
a. Kinetic analysis
of the progress curves for the slow onset of inhibition of wild-type
MR using a two-step kinetic mechanism gave K
i and K
i* values of 5.1 ±
1.8 and 0.26 ± 0.08 μM, respectively. Hence, wild-type
MR binds 2-FPBA with an affinity that exceeds that for the substrate
by ∼3000-fold. K164R MR was inhibited by 2-FPBA, while K166R
MR was not inhibited, indicating that Lys 166 was essential for inhibition.
Unexpectedly, mass spectrometric analysis of the NaCNBH3-treated enzyme–inhibitor complex did not yield evidence of
an iminoboronate adduct. 11B nuclear magnetic resonance
spectroscopy of the MR·2-FPBA complex indicated that the boron
atom was sp3-hybridized (δ 6.0), consistent with
dative bond formation. Surprisingly, X-ray crystallography revealed
the formation of an Nζ–B dative bond between
Lys 166 and 2-FPBA with intramolecular cyclization to form a benzoxaborole,
rather than the expected iminoboronate. Thus, when o-carbonyl arylboronic acid reagents are employed to modify proteins,
the structure of the resulting product depends on the protein architecture
at the site of modification.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.